Breast Adenocarcinoma, Prostate Cancer (Adenocarcinoma)
Conditions
Brief summary
The study will include the prospective acquisition of optimized MR imaging data of prostate and breast patients treated with radiotherapy (RT). Within the prospective study, biological specimens from patients undergoing in-room biopsy before RT, will be collected. Histological evaluation and cell culture (and organoid preparation) will be conducted, and samples/organoids will be irradiated with RT for biological validation.
Interventions
OTHERprostate patient
patients with prostate cancer treated with RT at IEO
OTHERbreast patients
patients with breast cancer treated with RT at IEO
Sponsors
European Institute of Oncology
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
for prostate patients: * Unifocal infiltrating ductal breast carcinoma, non-special histotype * clinical stage T1-T2,N0 * No contraindications to MRI, or metal joint prostheses from knee to shoulder included, or femoral stent. * Patients aged \>18 years * Good general condition (ECOG 0-2) * Expected active treatment (crioablation or surgery or radiotherapy ).
Exclusion criteria
*
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Generation of in-silico tumor model | 1 year | generate an in-silico tumour model able to describe tumour microstructure and its interaction with the radiation beam |
| Personalization of the tumour model with patient-specific MR imaging data | 1 year | personalize the tumour model implemented in A1 with patient-specific MR imaging data for tumour characterization and treatment outcome prediction, relying on retrospective data |
| Improvement of personalized tumor-models | 3 years | Improvement of the implemented models, by relying on advanced agnetic Resonance Imaging (MRI) data acquired prospectively |
| Evaluation of tumor model in describing the in-vivo microstructural and radiobiological characteristics | 3 years | The evaluation of the implemented in-silico tumour model in describing the in-vivo microstructural and radiobiological characteristics, by collecting histopathological features and irradiating primary cell cultures. |
Countries
Italy
Contacts
Primary ContactGiulia Marvaso, MD
Outcome results
None listed